



Review

Harnessing donor unrestricted T-cells for new vaccines against tuberculosis



Simone A. Joosten^a, Tom H.M. Ottenhoff^a, David M. Lewinsohn^b, Daniel F. Hoft^c, D. Branch Moody^d, Chetan Seshadri^{e,f,*}, for the Collaboration for Tuberculosis Vaccine Discovery - Donor-Unrestricted T-cells Working Group, Bill and Melinda Gates Foundation

^a Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands

^b Department of Medicine, Division of Pulmonary & Critical Care Medicine, Oregon Health Sciences University, Portland, USA

^c Department of Internal Medicine, Saint Louis University, Doisy Research Center, 8th floor, 1100 S. Grand Blvd., St. Louis, MO 63104, USA

^d Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Boston, Harvard Medical School, USA

^e Department of Medicine, Division of Infectious Diseases, University of Washington, Seattle, USA

^f Tuberculosis Research & Training Center, University of Washington, Seattle, USA

ARTICLE INFO

Article history:

Received 12 November 2018

Received in revised form 2 April 2019

Accepted 13 April 2019

Available online 27 April 2019

Keywords:

Vaccine

Tuberculosis

Donor-unrestricted T-cells

Tetramers

ABSTRACT

Mycobacterium bovis bacille Calmette-Guérin (BCG) prevents extrapulmonary tuberculosis (TB) and death among infants but fails to consistently and sufficiently prevent pulmonary TB in adults. Thus, TB remains the leading infectious cause of death worldwide, and new vaccine approaches are urgently needed. T-cells are important for protective immunity to *Mycobacterium tuberculosis* (Mtb), but the optimal T-cell antigens to be included in new vaccines are not established. T-cells are often thought of as responding mainly to peptide antigens presented by polymorphic major histocompatibility complex (MHC) I and II molecules. Over the past two decades, the number of non-peptidic Mtb derived antigens for $\alpha\beta$ and $\gamma\delta$ T-cells has expanded rapidly, creating broader perspectives about the types of molecules that could be targeted by T-cell-based vaccines against TB. Many of these non-peptide responsive T-cell subsets in humans are activated in a manner that is unrestricted by classical MHC-dependent antigen-presenting systems, but instead require essentially nonpolymorphic presentation systems. These systems are Cluster of differentiation 1 (CD1), MHC related protein 1 (MR1), butyrophilin 3A1, as well as the nonclassical MHC class Ib family member HLA-E. Thus, the resulting T-cell responses can be shared among a genetically diverse population, creating the concept of donor-unrestricted T-cells (DURT). Here, we review evidence that DURT are an abundant component of the human immune system and recognize many antigens expressed by Mtb, including antigens that are expressed in BCG and other candidate whole cell vaccines. Further, DURT exhibit functional diversity and demonstrate the ability to control microbial infection in small animal models. Finally, we outline specific knowledge gaps and research priorities that must be addressed to realize the full potential of DURT as part of new TB vaccine approaches.

© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Contents

1. The tuberculosis vaccine challenge.....	3023
2. Donor-unrestricted T-cells (DURT).....	3023
3. Mycobacterial antigens presented by MR1.....	3024
4. Mycobacterial antigen presentation by CD1.....	3024
5. $\gamma\delta$ T-cell response to Mtb.....	3024
6. HLA-E presentation of Mtb antigens.....	3024
7. Functional diversity and microbial control by DURT.....	3025

* Corresponding author at: University of Washington Medical Center, 750 Republican Street, Room E663, Seattle, WA 98109, USA.

E-mail address: seshadri@u.washington.edu (C. Seshadri).

8. Harnessing DURT's for TB vaccines	3025
9. Human studies with whole cell mycobacterial vaccines	3026
10. Summary	3027
Declaration of interests	3027
Acknowledgements	3027
References	3027

1. The tuberculosis vaccine challenge

Mycobacterium tuberculosis (Mtb) was responsible for over ten million infections and 1.6 million deaths worldwide in 2017 [1]. *M. bovis* bacille Calmette–Guérin (BCG) is the only licensed vaccine for tuberculosis (TB) and provides protection against disseminated forms of the disease in children but is inconsistent in preventing pulmonary TB in adults [2,3]. Since adults with pulmonary TB are thought to be the primary transmitters of Mtb, control of the epidemic will require more than the current generation of BCG vaccines. A major approach to vaccination is inducing T-cell responses to Mtb antigens because several lines of evidence indicate a role for T-cell mediated immunity in controlling the clinical course of tuberculosis. Studies in mouse and non-human primate models (NHP) have demonstrated the essential role of T-cells in conferring protection against challenge with Mtb [4–6]. In natural infection, CD4⁺ T-cell depletion as a result of human immunodeficiency virus (HIV) co-infection has also been associated with increased risk of pulmonary and extrapulmonary tuberculosis [7]. However, it is not known which mycobacterial antigens are targeted by protective T-cell responses, though water soluble secreted proteins have emerged as lead candidates for subunit vaccines.

The experience to date with subunit vaccines has been mixed. The development of MVA85A, a recombinant virally vectored vaccine expressing the Mtb protein Ag85A was based on the idea that boosting T-cell immunity to a single immunodominant protein antigen would be sufficient to boost prior BCG induced protective immunity [8,9]. However, when MVA85A was provided as a booster vaccine following priming BCG vaccination in South African infants, it failed to prevent Mtb infection and TB disease compared to BCG alone, despite the induction of polyfunctional and IL-17 producing CD4⁺ T-cells [10]. By contrast, a recombinant protein subunit vaccine known as M72 (a fusion protein composed of Mtb32A and Mtb39A) used in combination with a potent adjuvant (AS01_E) showed over 50% protective efficacy against pulmonary TB in Mtb-infected adults [11].

Another strategy has been to use whole cell mycobacterial vaccines, such as BCG. There is demonstrated heterogeneity in the T-cell response induced by BCG, suggesting that not all antigens are recognized equally by T-cells in a genetically diverse population [12,13]. Paradoxically, BCG vaccinated infants with a higher frequency of activated T-cells were shown to be at risk of TB disease progression [14]. Finally, revaccination of South African adolescents with BCG was shown to reduce acquisition of Mtb infection as measured by sustained conversion of an interferon-gamma release assay (IGRA) [15]. Collectively, the data suggest that while T-cells are important to controlling Mtb infection, not all vaccine strategies induce T-cells of sufficient antigenic breadth, functional diversity, or magnitude to confer protection against Mtb.

BCG is known to deliver immunogenic peptide antigens to antigen presenting cells, but the ‘whole organism’ nature of the vaccine means that non-peptide antigens are delivered as well. Generally, TB vaccinologists have not considered the potential importance of donor-unrestricted T-cells that respond to non-protein antigens produced by mycobacteria. Our goal with this review is to

summarize the current state of knowledge on donor-unrestricted T cells in microbial pathogenesis, with a focus on Mtb. We outline specific knowledge gaps and research priorities which must be tackled in order to realize the full potential of non-peptide antigens in new vaccines for TB.

2. Donor-unrestricted T-cells (DURT's)

Peptide antigens are presented to CD8⁺ and CD4⁺ T-cells by highly polymorphic major histocompatibility complex (MHC) Class I and Class II molecules, which have been studied extensively in TB [16]. However, many T-cells can be activated by more recently discovered non-MHC antigen presenting systems. MHC related protein 1 (MR1) is a MHC Class I-like protein that presents microbial metabolites, including derivatives of vitamin B such as 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil (5-OPRU) [17,18] and certain drugs, to T-cells [17,19,20]. Cluster of differentiation 1 (CD1) is also structurally homologous to MHC Class I but evolved to present microbial and mammalian lipids to T-cells, including $\gamma\delta$ T-cells [21–24]. Butyrophilin 3A1 was recently shown to facilitate recognition of ‘phosphoantigens,’ small molecules like isopentenyl pyrophosphate, by $\gamma\delta$ T-cells [25,26]. Finally, human leukocyte antigen E (HLA-E) can present peptides and glyco-peptides from various pathogens to T-cells [27–29].

Whereas the MHC Class I and Class II genes are the most polymorphic in the human genome, MR1, CD1 and butyrophilins are virtually non-polymorphic. The known single nucleotide polymorphisms are not known to strongly affect function. Moreover, some CD1-restricted and MR1-restricted T-cells express a partially invariant T-cell receptor (TCR) that is shared across genetically unrelated individuals [30,31]. Because the specific T-cells that recognize antigens presented by these presentation pathways are not restricted to the genome of the donor, they have acquired the moniker ‘donor-unrestricted T-cells’ or DURT's [32]. The donor-unrestricted nature of antigen presentation carries particular importance for vaccine development since a single vaccine immunogen could be designed to target the entire global population without respect to host genetic factors.

Although tools to enumerate DURT's are currently limited, estimations indicate that up to 5% of circulating peripheral human T-cells are CD1-restricted, another 5% is MR1-restricted and also an estimated 5% of peripheral T-cells are $\gamma\delta$ T-cells [33]. In addition to the peripheral compartment, DURT's also home to tissues and may accumulate locally. MR1-restricted T-cells in particular have a phenotype that suggest preferential homing to tissues. In the liver, up to 45% of lymphocytes may be MAIT cells, but also intestines contain considerable proportions of MAIT cells [34]. $\gamma\delta$ T-cells are abundantly present in the human skin, and represent a major T-cell population in both epidermis and dermis [35]. Intestinal intraepithelial lymphocytes are comprised of 37% $\gamma\delta$ T-cells, thus $\gamma\delta$ T-cells represent one of the major population of large intestinal lymphocytes [36]. Enumeration of CD1-restricted T-cells in tissue samples was limited, although autoreactive CD1-restricted T-cells do express skin homing receptors such as cutaneous lymphocyte antigen (CLA) [37]. Since HLA-E restricted T-cells recognize a large

array of antigens and lack specific surface markers their absolute frequencies remain unknown [38]. However, the abundance of HLA-E recognition in experimental vaccination studies indirectly suggests that these cells may be abundantly present [39]. In the following sections, it is not our intention to broadly review DURT biology, but rather focus on specific studies that highlight their potential for TB vaccine development. Several recent reviews summarize the evolution, genetics, biochemistry, and immunology of DURTs and their ligands [33,38,40,41].

3. Mycobacterial antigens presented by MR1

MR1 is among the most evolutionarily conserved MHC class I related molecules among mammals [42,43]. An MR1 polymorphism resulting in low mRNA expression was associated with TB meningitis [44]. Further, mucosal associated invariant T-cells (MAIT cells) in patients with active tuberculosis show an activated phenotype, suggesting they are readily activated *in vivo*. MAIT cells recognize Mtb infected cells in an MR1-dependent manner and express a semi-invariant T-cell receptor characterized by the use of the TRAV1-2 variable region and certain joining regions [45,46]. However, recent data suggest that MAIT cell clones expressing TCRs that are distinct from the canonical variable and joining regions can also respond to MR1-presented ligands [47]. MR1 antigens include 5-OPRU and ribityl lumazines, which are produced by many bacteria and fungi, as well as photolumazines which are produced by mycobacteria [47–50].

As these antigens are small molecules derived from microbial biosynthesis, little is known at present about how best to deliver these molecules for T-cell activation *in vivo*. In particular, the most potent antigens like 5-OPRU are sensitive to degradation, so the synthesis of stable MR1 ligands is a current challenge. Two reports using mouse models have demonstrated that exogenous delivery of MR1 ligands resulted in stable expansion of lung resident MR1-restricted T-cells [51,52]. Another study showed that challenge of human volunteers with *Salmonella paratyphi* resulted in the expansion of MR1-restricted T-cells with associated clonotypic expansions of selected MAIT-cells [53]. Whether or not these vaccine-induced expansions result in stable long-term memory populations remains to be determined.

4. Mycobacterial antigen presentation by CD1

Humans express four CD1 antigen presenting molecules (CD1a, CD1b, CD1c, CD1d), which vary in the configuration of their binding grooves, patterns of cellular expression, and subcellular trafficking [54]. By contrast, mice express only two nearly identical orthologs of human CD1d, so this model has only provided a narrow window into the role of CD1d-restricted T-cells in TB [4]. Evolutionary genetic analysis suggest that mice are the exception among mammals, most of which have expanded CD1 gene families similar to humans [40]. These data highlight the need to understand the distinct functions of CD1a, CD1b, and CD1c. Though CD1 proteins exhibit limited structural variation, a polymorphism in CD1a that is associated with low surface expression and T-cell activation was shown to be associated with TB [55,56]. CD1b is expressed in TB granulomas and may locally activate lipid reactive T-cells [57].

CD1 presented antigens were first discovered in the context of mycobacteria and focused on the long chain lipid, mycolic acid, followed later by structurally related glycolipid antigens, glucose monomycolate and glycerol monomycolate, which are all presented by CD1b [23,58,59]. Diacylated sulfotrehalose is structurally distinct but also a mycobacterial glycolipid antigen presented by CD1b [60]. Mycobacterial lipopeptide and mycoketide antigens

are presented by CD1a and CD1c, respectively [58,61]. These lipid antigens have been chemically synthesized in high yield. Further, defining the structure of lipid ligands has facilitated studies into the molecular requirements of T-cell recognition of lipid antigens [62]. More importantly, these chemically defined reagents have enabled the development of tetramers to probe the functions of human antigen-specific T-cells, and have begun to be used as sub-unit vaccines in small animal models [21,63–66]. CD1b tetramers facilitated the isolation of T-cells that recognized glucose monomycolate and subsequent TCR repertoire analysis. The TCR repertoire was diverse, expanding upon previously reported conserved motifs and demonstrating clonal expansion in patients with active pulmonary TB [67]. Thousands of mycobacterial peptide antigens have been described, but the number of chemically defined CD1 lipid antigens is less than ten. Thus, much work remains to be done in comprehensively characterizing the T-cell activating lipid antigens produced by Mtb.

5. $\gamma\delta$ T-cell response to Mtb

$\gamma\delta$ T-cell subsets in humans are typically categorized according to the specific TCR- δ chain variable segment. The most abundant is the V δ 2 expressing subset, which accounts for nearly 90% of $\gamma\delta$ T-cells in adult peripheral blood, and is usually paired with the V γ 9 gene segment [68]. V γ 9 V δ 2 T-cells are activated by alkylpyrophosphates and ‘phosphoantigens’ that are produced by mammalian cells as well as intracellular pathogens, including Mtb. Phosphoantigen recognition is mediated by butyrophilin 3A1 (BTN3A1) molecules, though the precise molecular mechanism by which this occurs has been controversial. The most recent studies suggest that phosphoantigens bind the intracellular domain of BTN3A1, leading to a conformational change on the extracellular domain, rather than being in direct contact with the T-cell receptor after binding the extracellular domain [25,26,69,70].

The BTN3A1 gene expresses some degree of polymorphism, and initial sequence comparisons within the 1000 Genomes Project revealed 57 alleles encoding 33 allotypes [71]. However, most allotypes are rare, and only 8 allotypes have frequencies exceeding 1% in specific populations [71]. The IgV domain of the BTN3A1 molecule is thought to be important for the direct activation of V γ 9V δ 2 TCR, and the IgV domains expressed by BTN3A1, BTN3A2 and BTN3A3 are highly conserved and strongly homologous. These findings suggest that all 3 BTN3 molecules may be involved in regulation of V γ 9 V δ 2 T-cell activation [71]. Recently, 6-O-methylglucose-containing lipopolysaccharides (mGLP) were identified as $\gamma\delta$ T-cell antigens specifically produced by Mtb that activate a subset of V γ 9 V δ 2 T-cells [72]. Though less abundant in blood, V δ 1 and V δ 3 expressing T-cells have been shown to recognize lipid antigens presented by CD1c and CD1d proteins [21,22,24,73,74]. Specifically, V δ 1 T-cells have been shown to recognize mycobacterial phosphomycoketide antigens presented by CD1c [24]. In addition, $\gamma\delta$ T-cells specific for Mtb peptides have been identified that might contribute to protection [75–77]. Thus, mGLP and mycoketides could plausibly serve as specific antigens in a TB vaccine designed to activate $\gamma\delta$ T-cells.

6. HLA-E presentation of Mtb antigens

HLA-E has two alleles, HLA-E*01:01 (E^R) and *01:03 (E^G), which differ in a single amino acid at position 107 (arginine or glycine), which is outside the peptide binding groove [78]. Whether HLA-E^R and HLA-E^G display functional differences has not been studied in detail [78,79], but HLA-E^G homozygous cells express higher levels of HLA-E and had higher peptide-binding affinity. HLA-E classically presents signal sequence peptides from HLA class Ia

alleles, and as such regulates innate immunity by inhibiting NK-cell activation through ligation to NKG2A/CD94 [80]. CMV peptides were the first identified ligands presented by human HLA-E and recognized in a TCR-dependent manner [81]. Subsequent work has also demonstrated that mycobacterial peptides and glycopeptides are presented by HLA-E to CD8⁺ T-cells [28,29,82,83]. The crystal structure of HLA-E bound to an Mtb-derived peptide antigen revealed flexibility of the conformation of bound peptides despite preferred primary anchor residues [84]. CMV vector based TB vaccination studies in rhesus macaques suggested that there is a very high density of MHC-E (the primate equivalent of HLA-E) epitopes, with an estimated average of ~4 epitopes per 100 amino acids, supporting the idea that additional epitopes for HLA-E presentation are yet to be discovered in the Mtb proteome [85].

7. Functional diversity and microbial control by DURT

MR1-restricted T-cells have features of both innate and adaptive immune cells that preclude simple categorization. MAIT-cells in thymus and peripheral blood have the capacity to secrete proinflammatory cytokines such as IFN- γ and TNF- α , as well as cytolytic capacity [86–88]. While MAIT cells can respond to Mtb through the TCR, they can also respond to environmental signals most notably IL-12, IL-18, and TLR stimulation [47,89–92]. Thus, MR1-restricted T-cells, particularly those in close proximity to microbial infection, might possess enhanced anti-microbial functions. Notably, one study demonstrated that a murine population of CD4, CD8 double negative (DN) MAIT could inhibit mycobacterial growth in an nitric oxide dependent fashion [93]. In mice, MAIT cells have been shown to facilitate the control of *Klebsiella pneumoniae*, *Mycobacterium bovis* BCG, *Francisella tularensis*, and *Legionella longbeachiae* [52,94–98]. While mice have MAIT cells, their frequency is markedly lower than seen in humans, and their phenotype seems skewed towards the production of IL-17, which is not typically seen in humans.

The initial description of the functions of CD1-restricted T-cells targeting mycobacteria were the result of studies on *in vitro* derived human T-cell clones. These showed a strong bias toward Th1 phenotypes, as characterized by the production of IFN- γ and TNF- α but not IL-4 [99]. These cells also displayed cytotoxic capacity and were able to lyse antigen-pulsed or Mtb-infected target cells [99,100]. Studies using an *ex vivo* functional assay have confirmed and extended these findings by revealing polyfunctional phenotypes characterized by simultaneous production of IFN- γ , TNF- α , IL-2, and CD40L [101]. Total lipid reactive T-cells were detected in individuals with Mtb infection, but not in patients with active TB disease until two weeks after initiation of chemotherapy [102]. Mycolic acid specific CD1 restricted human T-cell populations producing both IFN- γ and IL-2 were detected in patients with active pulmonary TB disease, but not in BCG-vaccinated individuals without Mtb infection [103]. TCRs mediate recognition of mycobacterial phospholipids presented by CD1c, and there did not seem to be a discernable pattern even among TCRs recognizing the same or similar antigens [104]. A humanized mouse model of CD1 was recently developed that recapitulates the expression pattern and immunology of CD1a, CD1b and CD1c in humans [105]. Adoptive transfer studies in this system have shown that mycolic acid-specific T-cells can confer modest protection against Mtb challenge [106]. A guinea pig study examining aerosol Mtb challenge after vaccination with mycobacterial lipids incorporated into liposomes showed a reduction in the size but not the number of lung lesions [107]. Thus, lipid-specific T-cells induced by vaccination could plausibly provide protective immunity against Mtb in humans. However, a number of questions remain, including the functions of these T-cells *in vivo* and at sites of infection, as well as whether they can be used to generate durable immunity.

The major subsets of $\gamma\delta$ T-cells, defined based on the γ or δ chain expressed, differ markedly between mice and humans. Therefore, it is unclear whether the literature describing $\gamma\delta$ T cell function in mice predicts the function of human V δ 1⁺ or V δ 2⁺ T cells. In cattle, $\gamma\delta$ T-cells accumulate quickly in the early phase of *M. bovis* infection, but decrease rapidly upon the arrival of other cells, possibly contributing to the early stages of granuloma formation [108]. Circulating $\gamma\delta$ T-cells from *M. bovis* exposed animals produced more IFN- γ and CCL2, expressed higher amounts of cytolytic molecules, and lysed BCG-infected target cells at higher efficiency compared to naive animals [109]. Similar to the finding in humans that BCG vaccination induces expansion *in vivo* of a memory population of V γ 9 V δ 2 T-cells [110], a rapid and robust expansion of $\gamma\delta$ T-cells was observed in BCG or Mtb-infected rhesus macaques [111,112]. $\gamma\delta$ T-cell responses in NHP can specifically be boosted by addition of phosphoantigens to protein subunit vaccines [113]. Adoptive transfer of $\gamma\delta$ T-cells in NHP reduced the bacterial burden and limited disease to the infected lobe by prevention of dissemination [114]. $\gamma\delta$ T-cells in peripheral blood of TB patients produced more IL-17 compared to those from healthy controls, however upon antigenic restimulation, more IFN- γ producing $\gamma\delta$ T-cells were present in peripheral blood of TB patients [115]. Human $\gamma\delta$ T-cells can reduce the burden of mycobacteria *in vitro* [116], but also provide helper functions to activate more classical components of the immune system [117]. $\gamma\delta$ T-cells can either have direct lytic effects on mycobacteria but can also activate monocytes to produce TNF- α and thereby activate intracellular pathways to kill mycobacteria [118]. Thus $\gamma\delta$ T-cells might be functionally important in reducing the burden of mycobacteria by direct effector activity, but may contribute indirectly by activation of other key immune players.

Human HLA-E restricted CD8⁺ T-cells express cytolytic effector molecules such as granzyme, perforin and granzymes [82,119], and most Mtb specific HLA-E restricted CD8⁺ T-cell lines have cytolytic activity towards Mtb or BCG infected macrophages [28]. These T-cells were also able to inhibit intracellular Mtb growth in human macrophages [82]. However, these T-cells did not produce high levels of IFN- γ typical of Th-1 T-cells, but rather the hallmark Th-2 cytokines IL-4, IL-5 and IL-13 and the associated transcription factor GATA-3 [82,119,120]. Qa-1 is the murine homolog of HLA-E and has been shown to bind and present human HLA-E binding peptides to murine CD8⁺ T-cells with cytolytic and regulatory activity [121]. Knock-out studies confirmed a direct role for Qa-1 in mediating a protective immune response against Mtb by regulating histopathology and bacterial burden [121]. These results support and are in agreement with the above discussed human studies, and thus mice may be considered as a model system to guide HLA-E based vaccine evaluation, albeit with all general limitations of TB vaccine evaluation in mice. Presentation of Mtb peptides by HLA-E in non-human primates likely occurs because the molecules are highly conserved across primate species [122]. The first evaluation of an attenuated rhesus CMV (RhCMV) vaccine showed strong protection against simian immunodeficiency virus (SIV) infection in rhesus macaques, and this protection was due, in part, to HLA-E restricted T-cells [39,123,124]. Strong protection against tuberculosis was also observed following vaccination with RhCMV vectors, but HLA-E restricted T-cells were shown to be redundant in this system [85]. Together these studies suggest a contribution of HLA-E restricted T-cells to protective immunity against TB.

8. Harnessing DURT for TB vaccines

For all of the DURT discussed above, the antigenic targets, cellular presentation pathways, and molecular mechanisms of T-cell activation are now well understood. Thus, current and future

research must focus on identifying the extent to which their activation results in durable immunological memory or protective effects in the acute setting. Surmounting these knowledge gaps will require a coordinated strategy by funders, academic labs, and industry (Table 1).

The first major hurdle is to ensure the availability of sufficient quantity of stable DURT antigens with which to study and optimize vaccine formulation. As described above, peptides and lipids presented by HLA-E and CD1, respectively, are already available as stable reagents in high yield. Many Mtb lipid antigens have been synthesized for the CD1 system and have been successfully validated in vitro or with tetramers [21,64,125–127]. However, MR1 ligands are inherently unstable and the $\gamma\delta$ T cell ligand mGLP is complex and has yet to be synthesized.

Once pure ligands are available, the next challenge will be to determine how to formulate them as vaccines. The biochemistry governing solubility of peptides, lipids, and small molecules may preclude co-formulation and require parallel development strategies. At the same time, selection of adjuvants to include or whether adjuvants are required at all will be another challenge. Some mycobacterial lipid antigens, such as phosphatidyl-*myo*-inositol mannosides, may fortuitously act as both antigen and adjuvant by activating Toll-like receptor pathways [128,129]. Lipid antigens may also lend themselves easily to co-formulation with lipophilic adjuvants already in clinical use, such as monophosphoryl lipid A or trehalose dibehenate [130,131]. Nanocarriers may also be employed to enhance delivery of lipid components such as mycolic acid to phagocytic immune cells, in particular following nasal immunization [132]. Alternatively liposomes may be employed as packaging for hydrophobic molecules such as lipoarabinomannan to promote uptake and presentation by antigen presenting cells [133]. Solving challenges in antigen production, purification and delivery will require expertise in medicinal chemistry, adjuvants, and product development that is under-represented within the DURT field.

Another hurdle is to develop animal models which more faithfully represent human biology. Because of the substantial differences between humans and mice for most DURTs, as discussed above, the optimal strategy may be to focus on non-human primates (NHP). NHP faithfully reproduce the spectrum of human tuberculosis, including active pulmonary disease characterized by multicellular granulomas [134]. NHP have also been used extensively in the pre-clinical evaluation of tuberculosis vaccines [135,136]. MAIT cell frequency and phenotype in NHP is much like

that seen in humans [137]. V γ 9 V δ 2 T-cells were present in NHP and expanded after BCG vaccination [111]. CD1 studies in NHP have been limited but have suggested that a vaccine containing a liposomal formulation of a mycobacterial glycolipid antigen was immunogenic [138]. Finally, HLA-E was recently shown to be functionally conserved between NHP and humans [122]. These studies have demonstrated proof-of-concept for all four DURT populations, and now a coordinated effort is required to develop and validate the reagents required to study DURTs in NHP. This may take the form of human tetramers that have cross-species reactivity or species-specific tetramers, as was demonstrated for MR1 [137]. Tetramers would facilitate immunogenicity studies of vaccine formulations described above or investigation of immunodominance among DURTs after whole cell vaccination. We could also evaluate DURT vaccines as a ‘booster’ after BCG, which would be the most likely implementation in TB endemic countries. As with humans, a major advantage of DURT tetramers in NHP will be their application across a genetically diverse population.

9. Human studies with whole cell mycobacterial vaccines

Despite these challenges, we have an immediate opportunity to study DURTs as correlates of protective immunity. The clinical efficacy signals observed in the recently published trials using BCG revaccination and M72 provide an opportunity to study the association of DURTs with protection from Mtb infection and pulmonary TB, respectively [11,15]. These studies could be modeled on immune correlate studies of the RV144 vaccine for HIV, which compared the results of several standardized and validated assays [139]. Even though tetramers are available for CD1, MR1, and HLA-E, very few of these have been incorporated into assays that have undergone the rigorous process of standardization required for inclusion as an endpoint assay in a clinical trial [63,139]. This expertise is not typically present within academic labs practicing discovery science, so may require partnerships with assay developers in industry. Tetramer-based assays would find utility in a number of ongoing clinical trials evaluating whole cell vaccines which are poly-antigenic and would be expected to boost DURTs. SRL-172 is a heat killed non-tuberculous mycobacterial vaccine that was shown to prevent tuberculosis in a large study of HIV-infected adults in Tanzania [140]. A reformulated version known as DAR-901 has completed Phase I studies and is now in Phase II [141]. VPM1002 is a recombinant *M. bovis* BCG strain that has been engineered to express bacterial listeriolysin and showed enhanced immunogenicity in a Phase I study and is currently in Phase II/III evaluation [142]. Finally, MTBVAC is an attenuated strain of Mtb that is currently in Phase II trials [143].

As an extension of these immune correlate studies, which would necessarily be performed retrospectively, DURTs might be evaluated in studies of controlled human mycobacterial challenge. These studies have already begun using live BCG [144,145]. A whole cell vaccine for malaria consisting of irradiated sporozoites was shown to be highly effective at preventing blood stage malaria in controlled human malaria infection [146]. In follow up studies, $\gamma\delta$ T-cells were shown to be associated with vaccine induced protection [147,148]. Specifically, the frequency of V δ 2 expressing subset of $\gamma\delta$ T-cells before vaccination was correlated with decreased parasitemia after immediate (3 weeks) and late (21–25 weeks) challenge with *Plasmodium falciparum* [147]. As described above, V δ 2⁺ T-cells have also been shown to be important in controlling Mtb infection in vitro, in particular in the early stages post infection, likely bridging innate and adaptive ($\alpha\beta$ T-cells) [116,118,147]. A broader study of DURTs in a human TB challenge model would require validated reagents and assays, as described above.

Table 1

DURT Research Priorities for TB Vaccine Development. Donor-unrestricted T-cells (DURTs) are activated by Mtb antigens presented by non-polymorphic antigen presenting systems. These include MR1, CD1, HLA-E for $\alpha\beta$ T-cells and CD1 or butyrophilins for $\gamma\delta$ T-cells. The priorities are listed roughly in the order of importance.

Antigens	Optimize chemical synthesis of non-peptide antigens to achieve high yields of pure and stable compounds
Vaccines	Formulate DURT antigens with adjuvants to achieve subunit vaccines
Tetramers	Develop and validate DURT tetramers that can be used to quantify DURT frequencies and characterize their functional and phenotypic profiles. Tetramers will be incorporated into sample sparing assays to be employed in animal and human studies as below
Animal Studies	Establish non-human primate (NHP) models to evaluate • immunogenicity and efficacy of DURT vaccines • DURT correlates of protection in Mtb challenge studies.
Human Studies	Use tetramers to evaluate DURTs as • Immune correlates of risk in natural history studies • Immune correlates of protection in vaccine efficacy studies

10. Summary

In summary, targeting DURT offers a complementary path to traditional strategies for inducing classical T-cell immunity to peptide antigens by increasing the breadth of targeted antigens, the functions of induced T-cells and exploiting the essential monomorphism of the antigen presentation systems involved. Whole cell mycobacterial vaccines that naturally contain DURT antigens may mediate their protective effect through the induction of DURT. On the other hand, DURT antigens themselves may be of direct interest as vaccine immunogens. Coordination among funders, academic labs, and industry partners with expertise in product development will be required to overcome the hurdles in chemistry, animal models, and assay optimization outlined above to fully realize the potential of DURT for new TB vaccines.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors would like to acknowledge all the members of the CTVD DURT Working Group for helpful discussions and critical review of the manuscript. Listed in alphabetical order, these are John D. Altman, Samuel M. Behar, Yueh-hsiu Chien, Willem A. Hanekom, Mitchell Kronenberg, Louis J. Picker, Jonah B. Sacha, Thomas J. Scriba, Sally Sharpe, Emmanuel Treiner, Ildiko Van Rhijn, and Ann Williams. The authors also acknowledge the efforts of Adriaan Minnaard, Martine Gilleron, and Jacques Prandi for synthesizing mycobacterial lipid antigens that are available through the Bill and Melinda Gates Foundation Lipid Bank (OPP1190451 to C.S.).

References

- [1] World Health Organization. GLOBAL TUBERCULOSIS REPORT. WHO report, WHO, Geneva; 2017.
- [2] Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis: Off Publ Infect Dis Soc Am* 2014;58:470–80.
- [3] Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against *Mycobacterium tuberculosis* infection in children: systematic review and meta-analysis. *BMJ (Clin Res ed)* 2014;349:g4643. PMC4122754.
- [4] Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB. Susceptibility of mice deficient in CD1D or TAP1 to infection with *Mycobacterium tuberculosis*. *J Exp Med* 1999;189:1973–80. PMC2192974.
- [5] Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C, Klein E, et al. CD4 T cell depletion exacerbates acute *Mycobacterium tuberculosis* while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. *AIDS Res Hum Retroviruses* 2012;28:1693–702. PMC3505050.
- [6] Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne *Mycobacterium tuberculosis* infection in mice. *J Exp Med* 2001;193:271–80. PMC2195922.
- [7] Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. *New Engl J Med* 2013;368:745–55.
- [8] Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. *J Infect Dis* 2008;198:544–52. PMC2822902.
- [9] Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. *Eur J Immunol* 2010;40:279–90.
- [10] Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. *Lancet* 2013;381:1021–8.
- [11] Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. *New Engl J Med* 2018. PMC6151253.
- [12] Fletcher HA, Filali-Mouhim A, Nemes E, Hawkridge A, Keyser A, Njikan S, et al. Human newborn bacille Calmette-Guerin vaccination and risk of tuberculosis disease: a case-control study. *BMC Med* 2016;14:76. PMC4869393.
- [13] Boer MC, Prins C, van Meijgaarden KE, van Dissel JT, Ottenhoff TH, Joosten SA. *Mycobacterium bovis* BCG vaccination induces divergent proinflammatory or regulatory T cell responses in adults. *Clin Vacc Immunol* 2015;22:778–88.
- [14] Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. *Nature Commun* 2016;7:11290. PMC4832066.
- [15] Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of *M. tuberculosis* infection with H4:IC31 vaccine or BCG revaccination. *New Engl J Med* 2018;379:138–49. PMC5937161.
- [16] Rowland R, McShane H. Tuberculosis vaccines in clinical trials. *Expert Rev Vacc* 2011;10:645–58. PMC3409871.
- [17] Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. *Nature* 2014;509:361–5.
- [18] Kjer-Nielsen L, Patel O, Corbett AJ, Le NJ, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* 2012;491:717–23.
- [19] Keller AN, Eckle SB, Xu W, Liu L, Hughes VA, Mak JY, et al. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. *Nat Immunol* 2017;18:402–11.
- [20] Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* 2012;491:717–23.
- [21] Ly D, Kasmar AG, Cheng TY, de Jong A, Huang S, Roy S, et al. CD1c tetramers detect ex vivo T cell responses to processed phosphomycoketide antigens. *J Exp Med* 2013;210:729–41. PMC3620358.
- [22] Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B, et al. The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vdelta1 TCR. *Eur J Immunol* 2012;42:2505–10. PMC3743557.
- [23] Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. *Nature* 1994;372:691–4.
- [24] Roy S, Ly D, Castro CD, Li NS, Hawk AJ, Altman JD, et al. Molecular analysis of lipid-reactive Vdelta1 gammadelta T cells identified by CD1c tetramers. *J Immunol (Baltimore, Md: 1950)* 2016;196:1933–42. PMC4744554.
- [25] Sandstrom A, Peigne CM, Leger A, Crooks JE, Konczak F, Gesnel MC, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T cells. *Immunity* 2014;40:490–500. PMC4028361.
- [26] Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. *Nat Immunol* 2013;14:908–16.
- [27] Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, McNabb AL, Streblow DN, et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. *J Exp Med* 2002;196:1473–81.
- [28] Joosten SA, van Meijgaarden KE, van Weeren PC, Kazi F, Geluk A, Savage ND, et al. *Mycobacterium tuberculosis* peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. *PLoS Pathog* 2010;6:e1000782.
- [29] Harrif MJ, Wolfe LM, Swarbrick G, Null M, Cansler ME, Canfield ET, et al. HLA-E presents glycopeptides from the mycobacterium tuberculosis protein MPT32 to human CD8(+) T cells. *Sci Rep* 2017;7:4622. PMC5496856.
- [30] Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. *J Exp Med* 1993;178:1–16. PMC2191070.
- [31] Van Rhijn I, Kasmar A, de Jong A, Gras S, Bhati M, Doorenspleet ME, et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. *Nat Immunol* 2013;14:706–13. PMC3723453.
- [32] Van Rhijn I, Moody DB. Donor unrestricted T cells: a shared human T Cell response. *J Immunol (Baltimore, Md: 1950)* 2015;195:1927–32. PMC4549802.
- [33] Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. *Nat Immunol* 2015;16:1114–23.
- [34] Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. *Blood* 2011;117:1250–9.
- [35] Toulon A, Breton L, Taylor KR, Tenenhaus M, Bhavsar D, Lanigan C, et al. A role for human skin-resident T cells in wound healing. *J Exp Med* 2009;206:743–50. PMC2715110.
- [36] Deusch K, Luling F, Reich K, Classen M, Wagner H, Pfeffer K. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment. *Eur J Immunol* 1991;21:1053–9.
- [37] de Jong A, Pena-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB. CD1a-autoreactive T cells are a normal component of the human alphabeta T cell repertoire. *Nat Immunol* 2010;11:1102–9. PMC3131223.
- [38] Joosten SA, Sullivan LC, Ottenhoff TH. Characteristics of HLA-E restricted T-Cell responses and their role in infectious diseases. *J Immunol Res* 2016;2016:2695396. PMC5028793.

- [39] Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, et al. Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E. *Science* 2016;351:714–20.
- [40] Reinink P, Van Rhijn I. Mammalian CD1 and MR1 genes. *Immunogenetics* 2016;68:515–23. PMC5002277.
- [41] Van Rhijn I, Godfrey DI, Rossjohn J, Moody DB. Lipid and small-molecule display by CD1 and MR1. *Nat Rev Immunol* 2015;15:643–54.
- [42] Riegert P, Wanner V, Bahram S. Genomics isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. *J Immunol (Baltimore, Md: 1950)* 1998;161:4066–77.
- [43] Rodgers JR, Cook RG. MHC class Ib molecules bridge innate and acquired immunity. *Nat Rev Immunol* 2005;5:459–71.
- [44] Seshadri C, Thuong NT, Mai NT, Bang ND, Chau TT, Lewinsohn DM, et al. TR. A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis. *Genes Immun* 2017;18:8–14. PMC5269436.
- [45] Le BL, Martin E, Peguillet I, Guihot A, Froux N, Core M, et al. Antimicrobial activity of mucosal-associated invariant T cells. *Nat Immunol* 2010;11:701–8.
- [46] Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS Biol* 2010;8:e1000407.
- [47] Gold MC, McLaren JE, Reistetter JA, Smyk-Pearson S, Ladell K, Swarbrick GM, et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. *J Exp Med* 2014;211:1601–10.
- [48] Lepore M, Kalinichenko A, Calogero S, Kumar P, Paleja B, Schmalzer M, et al. Functionally diverse human T cells recognize non-microbial antigens presented by MR1. *eLife* 2017;6. PMC5459576.
- [49] Gherardin NA, Keller AN, Woolley RE, Le Nours J, Ritchie DS, Neeson PJ, et al. Diversity of T Cells restricted by the MHC class I-related molecule MR1 facilitates differential antigen recognition. *Immunity* 2016;44:32–45.
- [50] Harrieff MJ, McMurtrey C, Froyd CA, Jin H, Cansler M, Null M, et al. MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage. *Sci Immunol* 2018;3.
- [51] Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SB, et al. Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. *Mucosal Immunol* 2017;10:58–68.
- [52] Wang H, D'Souza C, Lim XY, Kostenko L, Pediongo TJ, Eckle SBG, et al. MAIT cells protect against pulmonary *Legionella longbeachae* infection. *Nature Commun* 2018;9:3350. PMC6105587.
- [53] Howson LJ, Napolitani G, Shepherd D, Ghabbane H, Kurupati P, Preciado-Llanes L, et al. MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with *Salmonella Paratyphi A*. *Nat Commun* 2018;9:253. PMC5772558.
- [54] Van Rhijn I, Ly D, Moody DB. CD1a, CD1b, and CD1c in immunity against mycobacteria. *Adv Exp Med Biol* 2013;783:181–97.
- [55] Seshadri C, Shenoy M, Wells RD, Hensley-McBain T, Andersen-Nissen E, McElrath MJ, et al. Human CD1a deficiency is common and genetically regulated. *J Immunol (Baltimore, Md: 1950)* 2013;191:1586–93. PMC3748949.
- [56] Seshadri C, Thuong NT, Yen NT, Bang ND, Chau TT, Thwaites GE, et al. A polymorphism in human CD1A is associated with susceptibility to tuberculosis. *Genes Immun* 2014;15:195–8. PMC3998877.
- [57] Chancellor A, Tocheva AS, Cave-Ayland C, Tezera L, White A, Al Dulayymi JR, et al. CD1b-restricted GEM T cell responses are modulated by Mycobacterium tuberculosis mycolic acid meromycolate chains. *Proc Natl Acad Sci United States of America* 2017;114. E10956–e64. PMC5754766.
- [58] Moody DB, Ulrichs T, Muhlecker W, Young DC, Gurucha SS, Grant E, et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. *Nature* 2000;404:884–8.
- [59] Layre E, Collmann A, Bastian M, Mariotti S, Czaplicki J, Prandi J, et al. Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells. *Chem Biol* 2009;16:82–92.
- [60] Gilleron M, Stenger S, Mazorra Z, Wittke F, Mariotti S, Bohmer G, et al. Libero G. Diacylated sulfolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. *J Exp Med* 2004;199:649–59. PMC2213295.
- [61] Moody DB, Reinhold BB, Guy MR, Beckman EM, Frederique DE, Furlong ST, et al. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. *Science* 1997;278:283–6.
- [62] Gras S, Van Rhijn I, Shahine A, Cheng TY, Bhati M, Tan LL, et al. T cell receptor recognition of CD1b presenting a mycobacterial glycolipid. *Nat Commun* 2016;7:13257. PMC5095289.
- [63] Layton ED, Yu KKQ, Smith MT, Scriba TJ, De Rosa SC, Seshadri C. Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination. *J Immunol Methods* 2018;458:44–52. PMC5960426.
- [64] James CA, Yu KKQ, Gilleron M, Prandi J, Yedulla VR, Moleda ZZ, et al. CD1b tetramers identify T cells that recognize natural and synthetic diacylated sulfolipids from mycobacterium tuberculosis. *Cell Chem Biol* 2018;25:392–402. e14. PMC5910231.
- [65] Kasmar AG, Van Rhijn I, Cheng TY, Turner M, Seshadri C, Schiefel A, et al. CD1b tetramers bind alphabeta T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. *J Exp Med* 2011;208:1741–7. PMC3171094.
- [66] Kasmar AG, Van Rhijn I, Magalhaes KG, Young DC, Cheng TY, Turner MT, et al. CD1a tetramers and dextramers identify human lipopeptide-specific T cells ex vivo. *J Immunol (Baltimore, Md: 1950)* 2013;191:4499–503. PMC3845436.
- [67] DeWitt WS, Yu KKQ, Wilburn DB, Sherwood A, Vignali M, Day CL, et al. A diverse lipid antigen-specific TCR repertoire is clonally expanded during active tuberculosis. *J Immunol (Baltimore, Md: 1950)* 2018;201:888–96. PMC6057832.
- [68] Sherwood AM, Desmarais C, Livingston RJ, Andriesen J, Haussler M, Carlson CS, et al. Deep sequencing of the human TCRgamma and TCRbeta repertoires suggests that TCRbeta rearranges after alphabeta and gammadelta T cell commitment. *Sci Transl Med* 2011;3. 90ra61. PMC4179204.
- [69] Gu S, Sachleben JR, Boughter CT, Nawrocka WI, Borowska MT, Tarrasch JT, et al. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vgamma9Vdelta2 T cell activation. *PNAS* 2017;114. E7311–e20. PMC5584448.
- [70] Wang H, Morita CT. Sensor function for butyrophilin 3A1 in prenyl pyrophosphate stimulation of human Vgamma2Vdelta2 T cells. *J Immunol (Baltimore, Md: 1950)* 2015;195:4583–94. PMC4848273.
- [71] Afrache H, Pontarotti P, Abi-Rached L, Olive D. Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family. *Immunogenetics* 2017;69:379–90.
- [72] Xia M, Hesser DC, De P, Sakala IG, Spencer CT, Kirkwood JS, et al. A Subset of Protective gamma9delta2 T cells is activated by novel mycobacterial glycolipid components. *Infect Immun* 2016;84:2449–62. PMC4995917.
- [73] Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. *Nature* 1992;360:593–7.
- [74] Mangan BA, Dunne MR, O'Reilly VP, Dunne PJ, Exley MA, O'Shea D, et al. Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vdelta3 T cells. *J Immunol (Baltimore, Md: 1950)* 2013;191:30–4. PMC3721026.
- [75] Xi X, Han X, Li L, Zhao Z. Identification of a new tuberculosis antigen recognized by gammadelta T cell receptor. *Clin Vacc Immunol CVI* 2013;20:530–9. PMC3623398.
- [76] Cheng C, Wang B, Gao L, Liu J, Chen X, Huang H, et al. Next generation sequencing reveals changes of the gammadelta T cell receptor repertoires in patients with pulmonary tuberculosis. *Sci Rep* 2018;8:3956. PMC5834497.
- [77] Ding Y, Ma F, Wang Z, Li B. Characteristics of the Vdelta2 CDR3 sequence of peripheral gammadelta T cells in patients with pulmonary tuberculosis and identification of a new tuberculosis-related antigen peptide. *Clin Vacc Immunol CVI* 2015;22:761–8. PMC4478511.
- [78] Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. *J Biol Chem* 2003;278:5082–90.
- [79] Grimsley C, Ober C. Population genetic studies of HLA-E: evidence for selection. *Hum Immunol* 1997;52:33–40.
- [80] Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature* 1998;391:795–9.
- [81] Hoare HL, Sullivan LC, Pietra G, Clements CS, Lee EJ, Ely LK, et al. Structural basis for a major histocompatibility complex class Ib-restricted T cell response. *Nat Immunol* 2006;7:256–64.
- [82] van Meijgaarden KE, Haks MC, Caccamo N, Dieli F, Ottenhoff TH, Joosten SA. Human CD8+ T-cells recognizing peptides from mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. *PLoS Pathog* 2015;11:e1004671.
- [83] McMurtrey C, Harrieff MJ, Swarbrick GM, Duncan A, Cansler M, Null M, et al. Lewinsohn DM. T cell recognition of Mycobacterium tuberculosis peptides presented by HLA-E derived from infected human cells. *PLoS ONE* 2017;12: e0188288. PMC5703486.
- [84] Walters LC, Harlos K, Brackenridge S, Rozbesky D, Barrett JR, Jain V, et al. Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. *Nat Commun* 2018;9:3137. PMC6081459.
- [85] Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, et al. Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. *Nat Med* 2018;24:130–43.
- [86] Gold MC, Ehlinger HD, Cook MS, Smyk-Pearson SK, Wille PT, Ungerleider RM, et al. Human innate Mycobacterium tuberculosis-reactive alphabetaTCR+ thymocytes. *PLoS Pathog* 2008;4:e39. PMC2242840.
- [87] Gold MC, Eid T, Smyk-Pearson S, Eberling Y, Swarbrick GM, Langley SM, et al. Lewinsohn DM. Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. *Mucosal Immunol* 2013;6:35–44. PMC3443511.
- [88] Koay HF, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. *Nat Immunol* 2016;17:1300–11.
- [89] Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Lewinsohn DM. Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS Biol* 2010;8:e1000407. PMC2893946.
- [90] Ussher JE, Bilton M, Attwood E, Shadwell J, Richardson R, de Lara C, et al. Willberg CB. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. *Eur J Immunol* 2014;44:195–203. PMC3947164.

- [91] Ussher JE, van Wilgenburg B, Hannaway RF, Ruustal K, Phalora P, Kurioka A, et al. TLR signaling in human antigen-presenting cells regulates MR1-dependent activation of MAIT cells. *Eur J Immunol* 2016;46:1600–14. PMC5297987.
- [92] Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, et al. MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. *Mucosal Immunol* 2015;8:429–40. PMC4288950.
- [93] Cowley SC, Hamilton E, Frelinger JA, Su J, Forman J, Elkins KL, et al. T cells control intracellular bacterial infections both in vitro and in vivo. *J Exp Med* 2005;202:309–19. PMC2212999.
- [94] Sakala IG, Kjer-Nielsen L, Eickhoff CS, Wang X, Blazevec A, Liu L, et al. Functional heterogeneity and antimycobacterial effects of mouse mucosal-associated invariant T cells specific for riboflavin metabolites. *J Immunol* (Baltimore, Md :1950) 2015;195:587–601. PMC4490942.
- [95] Georgel P, Radosavljevic M, Macquin C, Bahram S. The non-conventional MHC class I MR1 molecule controls infection by *Klebsiella pneumoniae* in mice. *Mol Immunol* 2011;48:769–75.
- [96] Chua WJ, Truscott SM, Eickhoff CS, Blazevec A, Hoft DF, Hansen TH. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. *Infect Immun* 2012;80:3256–67. PMC3418730.
- [97] Meierovics A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. *PNAS* 2013;110. E3119–28. PMC3746930.
- [98] Meierovics AI, Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. *J Exp Med* 2016;213:2793–809. PMC5110023.
- [99] Rosat JP, Grant EP, Beckman EM, Dascher CC, Sieling PA, Frederique D, et al. CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ alpha beta T cell pool. *J Immunol* (Baltimore, Md: 1950) 1999;162:366–71.
- [100] Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. *Science* 1998;282:121–5.
- [101] Seshadri C, Lin L, Scriba TJ, Peterson G, Freidrich D, Frahm N, et al. Cell responses against mycobacterial lipids and proteins are poorly correlated in South African adolescents. *J Immunol* (Baltimore, Md: 1950) 2015;195:4595–603. PMC4637215.
- [102] Ulrichs T, Moody DB, Grant E, Kaufmann SH, Porcelli SA. T-cell responses to CD1-presented lipid antigens in humans with *Mycobacterium tuberculosis* infection. *Infect Immun* 2003;71:3076–87. PMC155760.
- [103] Montamat-Sicotte DJ, Millington KA, Willcox CR, Hingley-Wilson S, Hackforth S, Innes J, et al. A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. *J Clin Invest* 2011;121:2493–503. PMC3104771.
- [104] Roy S, Ly D, Li NS, Altman JD, Piccirilli JA, Moody DB, et al. Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by alpha beta T cells. *PNAS* 2014;111. E4648–57. PMC4217448.
- [105] Felio K, Nguyen H, Dascher CC, Choi HJ, Li S, Zimmer MI, et al. CD1-restricted adaptive immune responses to *Mycobacteria* in human group 1 CD1 transgenic mice. *J Exp Med* 2009;206:2497–509. PMC2768849.
- [106] Zhao J, Siddiqui S, Shang S, Bian Y, Bagchi S, He Y, Wang CR. Mycolic acid-specific T cells protect against *Mycobacterium tuberculosis* infection in a humanized transgenic mouse model. *eLife*. 2015;4. PMC4718816.
- [107] Dascher CC, Hiromatsu K, Xiong X, Morehouse C, Watts G, Liu G, et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. *Int Immunol* 2003;15:915–25.
- [108] McGill JL, Sacco RE, Baldwin CL, Telfer JC, Palmer MV, Waters WR. The role of gamma delta T cells in immunity to *Mycobacterium bovis* infection in cattle. *Vet Immunol Immunopathol* 2014;159:133–43.
- [109] Rusk RA, Palmer MV, Waters WR, McGill JL. Measuring bovine gamma delta T cell function at the site of *Mycobacterium bovis* infection. *Veterinary Immunol Immunopathol* 2017;193–4. 38–49. PMC5703227.
- [110] Hoft DF, Brown RM, Roodman ST. Bacille Calmette-Guérin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. *J Immunol* (Baltimore, Md: 1950) 1998;161:1045–54.
- [111] Shen Y, Zhou D, Qiu L, Lai X, Simon M, Shen L, et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. *Science* 2002;295:2255–8. PMC2872146.
- [112] Lai X, Shen Y, Zhou D, Sehgal P, Shen L, Simon M, et al. Immune biology of macaque lymphocyte populations during mycobacterial infection. *Clin Experimen Immunol* 2003;133:182–92. PMC1808757.
- [113] Cendron D, Ingoure S, Martino A, Casetti R, Horand F, Romagne F, et al. A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct gamma delta and alpha beta T cell responses in primates. *Eur J Immunol* 2007;37:549–65.
- [114] Qaqish A, Huang D, Chen CY, Zhang Z, Wang R, Li S, et al. Adoptive transfer of phosphoantigen-specific gamma delta T cell subset attenuates mycobacterium tuberculosis infection in nonhuman primates. *J Immunol* (Baltimore, Md: 1950) 2017;198:4753–63. PMC5557270.
- [115] Peng MY, Wang ZH, Yao CY, Jiang LN, Jin QL, Wang J, et al. Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis. *Cell Mol Immunol* 2008;5:203–8. PMC4651291.
- [116] Spencer CT, Abate G, Blazevec A, Hoft DF. Only a subset of phosphoantigen-responsive gamma delta T cells mediate protective tuberculosis immunity. *J Immunol* (Baltimore, Md: 1950) 2008;181:4471–84. PMC2670066.
- [117] Abate G, Spencer CT, Hamzabegovic F, Blazevec A, Xia M. Mycobacterium-specific gamma delta T cells mediate both pathogen-inhibitory and CD40 ligand-dependent antigen presentation effects important for tuberculosis immunity. *Infect Immun* 2016;84:580–9. PMC4730576.
- [118] Spencer CT, Abate G, Sakala IG, Xia M, Truscott SM, Eickhoff CS, et al. Granzyme A produced by gamma(9)delta(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen. *PLoS Pathog* 2013;9:e1003119. PMC3542113.
- [119] Prezzemolo T, van Meijgaarden KE, Franken KL, Caccamo N, Dieli F, Ottenhoff TH, et al. Detailed characterization of human *Mycobacterium tuberculosis* specific HLA-E restricted CD8+ T-cells. *Eur J Immunol* 2017.
- [120] Caccamo N, Pietra G, Sullivan LC, Brooks AG, Prezzemolo T, La Manna MP, et al. Human CD8 T lymphocytes recognize *Mycobacterium tuberculosis* antigens presented by HLA-E during active tuberculosis and express type 2 cytokines. *Eur J Immunol* 2015;45:1069–81.
- [121] Bian Y, Shang S, Siddiqui S, Zhao J, Joosten SA, Ottenhoff THM, et al. Ib molecule Qa-1 presents *Mycobacterium tuberculosis* peptide antigens to CD8 + T cells and contributes to protection against infection. *PLoS Pathog* 2017;13:e1006384. PMC5435364.
- [122] Wu HL, Wiseman RW, Hughes CM, Webb GM, Abdulhaqq SA, Bimber BN, et al. The role of MHC-E in T Cell immunity is conserved among humans, rhesus macaques, and cynomolgus macaques. *J Immunol* (Baltimore, Md: 1950) 2018;200:49–60. PMC5736429.
- [123] Hansen SG, Piatak Jr M, Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. *Nature* 2013;502:100–4. PMC3849456.
- [124] Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. *Science* 2013;340:1237874. PMC3816976.
- [125] de Jong A, Arce EC, Cheng TY. CD1c presentation of synthetic glycolipid antigens with foreign alkyl branching motifs. *Chem Biol* 2007;14:1232–42. PMC2692252.
- [126] Guidard J, Collmann A, Garcia-Alles LF, Mourey L, Brando T, Mori L, et al. Fatty acyl structures of mycobacterium tuberculosis sulfolipid govern T cell response. *J Immunol* (Baltimore, Md: 1950) 2009;182:7030–7.
- [127] Van Rhijn I, Iwamy SK, Fodran P, Cheng TY, Gapin L, Minnaard AJ, Moody DB. CD1b-mycolic acid tetramers demonstrate T-cell fine specificity for mycobacterial lipid tails. *Eur J Immunol* 2017;47:1525–34. PMC5716475.
- [128] Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, et al. Different Toll-like receptor agonists induce distinct macrophage responses. *J Leukoc Biol* 2001;69:1036–44.
- [129] de la Salle H, Mariotti S, Angenieux C, Gilleron M, Garcia-Alles LF, Malm D, et al. Assistance of microbial glycolipid antigen processing by CD1e. *Science* 2005;310:1321–4.
- [130] Werninghaus K, Babiak A, Gross O, Holscher C, Dietrich H, Agger EM, et al. Adjuvanticity of a synthetic cord factor analogue for subunit *Mycobacterium tuberculosis* vaccination requires Fc gamma-Syk-Card9-dependent innate immune activation. *J Exp Med* 2009;206:89–97. PMC2626670.
- [131] Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garçon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. *Expert Rev Vacc* 2017;16:55–63.
- [132] Shang S, Kats D, Cao L, Morgun E, Velluto D, He Y, et al. Induction of mycobacterium tuberculosis lipid-specific T cell responses by pulmonary delivery of mycolic acid-loaded polymeric micellar Nanocarriers. *Front Immunol* 2018;9:2709. PMC6277542.
- [133] Kallert S, Zenk SF, Walther P, Grieshaber M, Weil T, Stenger S. Liposomal delivery of lipaarabinomannan triggers *Mycobacterium tuberculosis* specific T-cells. *Tuberculosis* (Edinburgh, Scotland). 2015;95:452–62.
- [134] Flynn JL, Gideon HP, Mattila JT, Lin PL. Immunology studies in non-human primate models of tuberculosis. *Immunol Rev* 2015;264:60–73. PMC4339213.
- [135] Laddy DJ, Bonavia A, Hanekom WA, Kaushal D, Williams A, Roederer M, et al. Toward tuberculosis vaccine development: recommendations for nonhuman primate study design. *Infect Immun* 2018;86:PMC5778361.
- [136] Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. *PLoS One* 2009;4:e5264. PMC2666807.
- [137] Greene JM, Dash P, Roy S, McMurtrey C, Awad W, Reed JS, et al. MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates. *Mucosal Immunol* 2017;10:802–13. PMC5397382.
- [138] Morita D, Hattori Y, Nakamura T, Igarashi T, Harashima H, Sugita M. T cell response to a mycolyl glycolipid is mediated by CD1c molecules in rhesus macaques. *Infection Immun* 2013;81:311–6. PMC3536160.
- [139] Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *New Engl J Med* 2012;366:1275–86. PMC3371689.
- [140] von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. *Aids* 2010;24:675–85.
- [141] von Reyn CF, Lahey T, Arbeit RD, Landry B, Kailani L, Adams LV, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. *PLoS One* 2017;12:e0175215. PMC5429024.

- [142] Grode L, Ganoza CA, Brohm C, Weiner 3rd J, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. *Vaccine* 2013;31:1340–8.
- [143] Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. *Vaccine* 2013;31:4867–73.
- [144] Blazevic A, Xia M, Turan A, Tennant J, Hoft DF. Pilot studies of a human BCG challenge model. *Tuberculosis (Edinburgh, Scotland)*. 2017;105: 108–12.
- [145] Minninnick A, Harris S, Wilkie M, Peter J, Stockdale L, Manjaly-Thomas ZR, et al. Optimization of a human bacille calmette-guerin challenge model: a tool to evaluate antimycobacterial immunity. *J Infect Dis* 2016;213:824–30. PMC4747614.
- [146] Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. *Science* 2013;341:1359–65.
- [147] Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. *Nat Med* 2016;22:614–23.
- [148] K.E. Lyke A.S. Ishizuka A.A. Berry S. Chakravarty A. DeZure M.E. Enama et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. *Proc Nat Acad Sci United States of America* 2017;114: 2711–6 PMC5347610.